BACE1 and Alzheimer disease: Its moderate activity towards BACE-1 (IC50 = 21 μM) claims for an additional anti-AD activity, that is the disruption of the amyloidogenic processing of APP ultimately leading to oligomers’ fibrillization and deposition.